Click here to close now.



Welcome!

News Feed Item

Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

"Harnessing Breakthroughs – Targeting Cures" is the theme of this year's AACR meeting and one that is mirrored throughout Lilly's early-stage oncology research. Lilly's oncology pipeline is among the most robust across the pharmaceutical industry and includes a broad range of large and small molecules being investigated to treat a wide range of cancers including lung, breast, colorectal, gastric, liver and hematologic malignancies. Lilly research presented at AACR will represent early findings from several of those early-stage clinical agents.

Data from bemaciclib, Lilly's CDK4/6 inhibitor LY2835219 as a potential treatment for metastatic breast cancer, has been accepted as a late-breaking presentation that will be included at AACR's Clinical Trials Symposium and will be featured in an official AACR-sponsored press conference.

"The CDK4/6 pathway is one of the most commonly implicated pathways in all cancers, making it an important area for research," said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. "The single-agent activity we've observed for bemaciclib is encouraging in this setting and we believe the data support the need for further development in metastatic breast cancer."

Lilly's B-Raf inhibitor LY3009120 will be highlighted at AACR's New Drugs on the Horizon special session where first data disclosures of promising, new anti-cancer compounds that target key pathways will occur. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.

"As we gain a better understanding about the distinct tumor biologies and other individual characteristics that make one tumor different than another, we are able to apply this knowledge to our development of potential new cancer treatments, such as those we are presenting at AACR," said Dr. Gaynor. "Each step we take during early-stage research – both in the lab and on clinical trials – leads us toward the same overall goal: to increase the number of treatment options available to patients."

Select Lilly early-stage pipeline studies, along with the times and locations of their data sessions, are highlighted below.

bemaciclib (LY2835219)

  • Abstract #CT232: Clinical Trials Symposium: Monday, April 7, 2014 1:30 pm1:50 pm
    • Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    • Author/Speaker: Amita Patnaik, M.D., FRCP(C)
    • Location: Room 25
    • Note: Abstract #CT232 to be presented at AACR press conference on April 6 at 7:30 am

B-Raf Inhibitor (LY3009120)

  • Abstract #7135: New Drugs on the Horizon Special Session: Sunday, April 6, 2014 3:45 pm to 4:10 pm
    • Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimer with activity against BRaf or Ras mutant tumor cells and minimal paradoxical activation
    • Author/Speaker: Sheng-Bin Peng, Ph.D.
    • Location: Room 29

c-MET Inhibitor (LY2801653)

  • Abstract #CT237: Clinical Trials Minisymposium: Monday, April 7, 2014 3:20 pm3:35 pm
    • Interim results of a first-in-human Phase I study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
    • Author/Speaker: Jimmy Hwang, M.D.
    • Location: Room 29
  • Abstract #4403: Poster Presentation: Tuesday April 8, 2014 1:00 pm to 5:00 pm
    • Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
    • Author/Speaker: S. Betty Yan, Ph.D.
    • Location: Hall A-E, Section 24

FGFR Inhibitor (LY2874455)

  • Abstract #CT215: Poster Presentation: Monday, April 7, 2014 8:00 am to 12:00 pm
    • A Phase 1 Study of LY2874455, a Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Cancer
    • Author/Speaker: Dr. Jeanne Tie
    • Location: Hall A-E, Section 38

P-LLY

This press release contains forward-looking statements about the potential of LY2835219, LY2801653, LY3009120 and LY2874455 as treatments for various cancers and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results for these products will be consistent with study findings to date, that these products will receive regulatory approvals, or will prove to  be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Media Inquiries:


Keri McGrath, Lilly Oncology

Neil Hochman, TogoRun

317-370-8394 (mobile)

212-453-2067 (office) / 516-784-9089 (mobile)

Email: [email protected]

Email: [email protected]

 

Eli Lilly and Company logo

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

 

SOURCE Eli Lilly and Company

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, will provide an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data profes...
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Fortunately, meaningful and tangible business cases for IoT are plentiful in a broad array of industries and vertical markets. These range from simple warranty cost reduction for capital intensive assets, to minimizing downtime for vital business tools, to creating feedback loops improving product design, to improving and enhancing enterprise customer experiences. All of these business cases, which will be briefly explored in this session, hinge on cost effectively extracting relevant data from ...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...